Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different cancer types. The tryptophan metabolite L-Kynurenine (Kyn) interacts with the ligand-activated transcription factor aryl hydrocarbon receptor (AHR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature communications Ročník 11; číslo 1; s. 4011 - 11
Hlavní autoři: Campesato, Luis Felipe, Budhu, Sadna, Tchaicha, Jeremy, Weng, Chien-Huan, Gigoux, Mathieu, Cohen, Ivan Jose, Redmond, David, Mangarin, Levi, Pourpe, Stephane, Liu, Cailian, Zappasodi, Roberta, Zamarin, Dmitriy, Cavanaugh, Jill, Castro, Alfredo C., Manfredi, Mark G., McGovern, Karen, Merghoub, Taha, Wolchok, Jedd D.
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 11.08.2020
Nature Publishing Group
Nature Portfolio
Témata:
13/1
13/106
13/109
13/21
13/31
38
38/77
38/88
42
45
631/250/251/1574
631/250/580
631/67/327
64
64/60
Aromatic compounds
Catabolism
CD8 antigen
Humanities and Social Sciences
Hydrocarbons
Immune checkpoint inhibitors
Immunosuppression
Immunotherapy
Inhibitors
Ligands
Lymphocytes
Lymphocytes T
Macrophages
Metabolites
multidisciplinary
Myeloid cells
PD-1 protein
Receptors
Science
Science (multidisciplinary)
Tryptophan
Tryptophan 2,3-dioxygenase
Tumors
ISSN:2041-1723, 2041-1723
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different cancer types. The tryptophan metabolite L-Kynurenine (Kyn) interacts with the ligand-activated transcription factor aryl hydrocarbon receptor (AHR) to drive the generation of Tregs and tolerogenic myeloid cells and PD-1 up-regulation in CD8 + T cells. Here, we show that the AHR pathway is selectively active in IDO/TDO-overexpressing tumors and is associated with resistance to immune checkpoint inhibitors. We demonstrate that IDO-Kyn-AHR-mediated immunosuppression depends on an interplay between Tregs and tumor-associated macrophages, which can be reversed by AHR inhibition. Selective AHR blockade delays progression in IDO/TDO-overexpressing tumors, and its efficacy is improved in combination with PD-1 blockade. Our findings suggest that blocking the AHR pathway in IDO/TDO expressing tumors would overcome the limitation of single IDO or TDO targeting agents and constitutes a personalized approach to immunotherapy, particularly in combination with immune checkpoint inhibitors. The tryptophan metabolite kynurenine is an endogenous ligand of the aryl hydrocarbon receptor (AHR). Here, the authors show that AHR targeting in IDO/TDO-expressing tumours counteracts a regulatory T cell/macrophage suppressive axis and synergizes with immune checkpoint blockade to hinder tumour growth.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-020-17750-z